OBJECTIVE: The purpose of this study was to determine whether serum and peritoneal fluid levels of fibroblast growth factor-2 (FGF-2) differ between women with and without endometriosis and to examine the relationship between proliferative activity in the endometriotic lesions and the levels of FGF-2 in serum and peritoneal fluid. STUDY DESIGN: Biopsy specimens of peritoneal endometriotic lesions (n = 25) were analyzed immunohistochemically regarding proliferative activity in stroma, glands, and blood vessels. The FGF-2 concentration was measured in peritoneal fluid and serum from 25 women with endometriosis and 14 healthy controls. RESULTS: Patients with endometriosis had higher serum concentrations of FGF-2 during both the proliferative and secretory menstrual phases than healthy women. Peritoneal fluid levels of FGF-2 differed significantly between women with high and low proliferative activity in their endometriotic lesions. CONCLUSION: Women with endometriosis have a higher serum level of FGF-2 than healthy controls.
OBJECTIVE: The purpose of this study was to determine whether serum and peritoneal fluid levels of fibroblast growth factor-2 (FGF-2) differ between women with and without endometriosis and to examine the relationship between proliferative activity in the endometriotic lesions and the levels of FGF-2 in serum and peritoneal fluid. STUDY DESIGN: Biopsy specimens of peritoneal endometriotic lesions (n = 25) were analyzed immunohistochemically regarding proliferative activity in stroma, glands, and blood vessels. The FGF-2 concentration was measured in peritoneal fluid and serum from 25 women with endometriosis and 14 healthy controls. RESULTS:Patients with endometriosis had higher serum concentrations of FGF-2 during both the proliferative and secretory menstrual phases than healthy women. Peritoneal fluid levels of FGF-2 differed significantly between women with high and low proliferative activity in their endometriotic lesions. CONCLUSION:Women with endometriosis have a higher serum level of FGF-2 than healthy controls.
Authors: Stephany P Monsanto; Andrew K Edwards; Juhua Zhou; Prakash Nagarkatti; Mitzi Nagarkatti; Steven L Young; Bruce A Lessey; Chandrakant Tayade Journal: Fertil Steril Date: 2015-12-14 Impact factor: 7.329
Authors: Vicki Nisenblat; Patrick M M Bossuyt; Rabia Shaikh; Cindy Farquhar; Vanessa Jordan; Carola S Scheffers; Ben Willem J Mol; Neil Johnson; M Louise Hull Journal: Cochrane Database Syst Rev Date: 2016-05-01
Authors: A Malutan; T Drugan; C Georgescu; R Ciortea; C Bucuri; A Bobric; M P Rada; D Mihu Journal: Acta Endocrinol (Buchar) Date: 2016 Jan-Mar Impact factor: 0.877
Authors: Christian M Becker; Paul Beaudry; Tae Funakoshi; Ofra Benny; Alexander Zaslavsky; David Zurakowski; Judah Folkman; Robert J D'Amato; Sandra Ryeom Journal: Am J Pathol Date: 2011-04 Impact factor: 4.307